Author: Donald McLean

Great Falls, Montana and Kyiv, Ukraine (May 14, 2025) – Cliniphai, an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences, today announced the appointment of Donna Wallace, MBA as Chief Compliance Officer. Wallace, who joined in April, will oversee Cliniphai’s global compliance programs and quality management systems, playing a critical role in ensuring that the company’s AI-powered solutions meet the highest standards for safety, effectiveness, and regulatory adherence.

With deep experience as a former quality and compliance leader for Medidata, Egnyte, and Organon, Wallace will lead the continued development of corporate standards and operational practices that reinforce Cliniphai’s commitment to ethical innovation and excellence.

“I am proud to step into the c-suite to provide leadership in promoting a culture of compliance and ethical conduct, while properly managing regulatory risks across our global operations,” said Wallace. “For years, I have been passionate about innovation and leveraging technology to advance patient outcomes, and I look forward to helping Cliniphai deliver solutions that are both transformational and also fully aligned with the high standards of quality and safety that our industry demands.”

Poised for AI growth

Wallace’s appointment comes at a pivotal time for Cliniphai, following the recent launch of Athena, its AI-powered clinical translation and localization workbench. Designed specifically for the life sciences industry, Athena streamlines complex translation processes with adaptive AI-driven support and human-in-the-loop control, addressing a major source of delays in clinical trial startups.

“AI is reshaping many workflows across our industry, and the right compliance is a critical foundation for everything we do at Cliniphai,” said Vladimir Mats, PhD, CEO, Cliniphai. “As we bring new AI-powered solutions to the market, Donna’s leadership will ensure that we continue to meet and exceed the trust that our clients place in us and help us continue to deliver innovation without compromise.”

Wallace emphasized the increasing role AI will play in the future of life sciences, noting the potential for AI to improve clinical research, enhance patient care, and reduce operational costs. She expects AI adoption across the industry to continue accelerating, particularly in streamlining the drug development process.

For more information or to request a demo of Cliniphai’s Athena, visit www.cliniphai.com or schedule a call at https://calendly.com/cliniphai.

About Cliniphai

Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences. The company’s flagship platform, Athena, is an AI-powered clinical translation and localization workbench focused on delivering secure, compliant, and high-quality solutions for life sciences, healthcare, and pharmaceutical organizations. Founded by industry veterans in clinical trial execution, technology development, and regulatory compliance, Cliniphai is redefining how organizations approach AI in life sciences without compromising accuracy, security, or compliance. For more information, visit www.cliniphai.com.

Media Contact
Don F. McLean, McLean Media
+1-734-716-4162

###

 

Great Falls, Mont. and Long Beach, Calif. (March 27, 2025) – Cliniphai, an AI Agent and Framework platform designed to solve complex challenges in life sciences, has announced a strategic partnership with Adherence, a digital health startup specializing in medication adherence predictive analytics. Adherence leverages real-world adherence data and behavioral insights to identify patterns, predict non-adherence risks, and drive targeted interventions. Through this collaboration, the two companies aim to expand access to high-quality adherence data, transforming how clinical translation and localization are implemented in global healthcare.

Starting today, Cliniphai’s Athena™ platform and the Adherence ATLAS™ (Adherence Tools and Location Analytics System) platform will come together to drive an unprecedented 24-hour global adherence initiative. ATLAS will collect and analyze more than 1,000 real-time adherence assessments from healthcare providers and patients across the world with support from Athena. In parallel, Cliniphai and Adherence are embarking on a landmark project to demonstrate how Athena’s human-guided, AI-augmented translation technology can streamline the localization of clinical trial endpoints and patient-facing materials to ensure faster timelines, greater cost-efficiency, and uncompromising clinical quality.

“This partnership represents a major step forward in advancing global adherence science and transforming how clinical trials engage diverse populations,” said Jason Martin, MS, MBA, Chairman and Co-Founder at Cliniphai. “Working alongside Philip Morisky and his team, we’re equally amplifying the reach and impact of the MMAS and demonstrating how Athena can redefine clinical translation by delivering high-quality, regulatory-compliant localizations with unprecedented speed, accuracy, and scale. Together, we’re setting a new standard for how life sciences organizations connect with patients and improve health outcomes worldwide.”

Raising the bar for global adherence and localization

The Morisky Medication Adherence Scale (MMAS) is a globally recognized, validated gold standard for measuring medication adherence in clinical trials and healthcare settings. As part of this collaboration, Cliniphai will localize MMAS condition-specific instruments into five additional languages, including Russian, Arabic, Chinese, Japanese, and French, with plans to expand to all 40 languages currently covered within the tool.

Key project objectives include:

• Faster localization, with early beta testing showing a potential 3x increase in speed compared to traditional methods and measuring through complete end-to-end timelines.

• Greater cost-efficiency, projecting a 2-3x reduction in cost for translation and localization processes for greater access and scalability.

• Maintaining clinical equivalence and compliance, by upholding MMAS’s clinical validity through expert reviews, cognitive field testing, and co-validation by Dr. Morisky’s expert network. All work aligns with ISPOR standards and best practices in global health research.

“This partnership helps us strengthen the clinical application of MMAS globally and gives us the opportunity to further expand language capabilities to improve accessibility and global adoption,” said Philip Morisky, Chief Optimus of Adherence. “It also accelerates the development of Athena as a trusted platform that addresses the critical challenge of ensuring that language is never a barrier to better data, deeper insights, and improved patient outcomes. Together, we are laying the foundation for a more inclusive and effective approach to medication adherence worldwide.”

A global call to action

On March 27, Adherence and its ATLAS platform will offer the world’s first real-time snapshot of global medication adherence, powered by MMAS assessments. The event will collect adherence data from every inhabited continent, providing a powerful lens into the behaviors and challenges that impact health outcomes globally.

The World Adherence Day initiative has already garnered participation commitments from several teaching hospitals and universities worldwide. Students, residents, and community health workers will conduct MMAS assessments within their local communities, pharmacies, and hospitals, generating meaningful data to inform future healthcare policies and practices.

Those interested can get involved in the following ways:

• Explore the ATLAS™ adherence map and watch real-time adherence data unfold live at tinyurl.com/atlasadherence (password: adherenceday2025).

• Contribute to the Global Study by participating in the MMAS-8 survey at tinyurl.com/atlasmmas.

• Universities, sponsors, and healthcare organizations are invited to take part in this historic initiative and gain early insights from this transformative data set. Sign up at tinyurl.com/atlasregister

For more information on Athena by Cliniphai, visit: www.cliniphai.com.

About Cliniphai

Cliniphai is an AI Agent and Framework platform purpose-built to solve complex challenges in life sciences that accelerates innovation, streamlines operations, and enables smarter decision-making across the entire value chain. The company’s flagship platform, Athena, is an AI-powered clinical translation and localization tool focused on delivering secure, compliant, and high-quality solutions for life sciences. Founded by industry veterans in clinical trial execution, technology development, and regulatory compliance, Cliniphai is redefining how organizations approach AI in life sciences—without compromising accuracy, security, or compliance. For more information, visit: https://www.cliniphai.com/.

About Adherence

Adherence, operated by Philip Morisky and his team of data scientists, is a global leader in advancing medication adherence science. Adherence develops and manages the many derivatives of the Morisky Medication Adherence Scales (MMAS), the internationally recognized gold standard for measuring and improving medication adherence in clinical trials, healthcare systems, and public health initiatives. Validated in thousands of peer-reviewed studies and used in over 100 countries, the MMAS provides healthcare professionals, researchers, and policymakers with reliable, actionable insights that enhance patient outcomes and support evidence-based decision-making. For more information, visit https://www.adherence.cc

Media Contact

Don F. McLean, McLean Media

+1-734-716-4162

###